Skip to content


 Efgartigimod (also known as Vyvgart) is a potential treatment for generalised myasthenia gravis (MG) developed by Argenx. 

How it works

Antibodies are proteins that the immune system produces in response to foreign molecules invading the body. They fall into five classes (IgG, IgA, IgM, IgD, and IgE) where each class acts slightly differently and responds to different threats. Most antibodies in the blood and fluid that surround tissues and cells belong to the IgG class. The antibodies that contribute to MG development and progression also belong to the IgG class. 

These IgC antibodies target a protein called the acetylcholine receptor, which binds to the neurotransmitter acetylcholine and plays a key role in nerve-muscle communication. Normally, the binding of acetylcholine to its receptor signals muscles to contract. However, because the immune system attacks acetylcholine receptors in MG, acetylcholine cannot bind to them efficiently and nerve cells cannot send a strong signal to muscles, resulting in muscle weakness. 

Normally, IgG antibodies circulating in the bloodstream are eventually broken down and recycled. A protein called neonatal Fc receptor (FcRn) helps to stabilize IgG antibodies and prevent this process. Vyvgart works by blocking this receptor, thereby increasing the rate at which IgG antibodies, including those driving MG, are broken down. By lowering the levels of disease-driving antibodies, the therapy is expected to ease MG symptoms. 

Vyvgart is administered via hour-long infusions into the bloodstream. Patients initially receive four weekly infusions over the course of four weeks, with additional treatment cycles administered based on clinical response.


Vyvgart is available through an Early Access to Medicines Scheme (EAMS). For more information on the scheme, please read through our FAQ for vyvgart (efgartigimod alfa) in the treatment of myasthenia gravis (gMG) here.

The treatment is currently being appraised by NICE, which will determine its availability on the NHS in England, Wales and Northern Ireland. The appraisal process is due to conclude in May 2024. More information about the NICE appraisal is available here.

Vygart is not available in Scotland following an assessment by the SMC that concluded it is not recommended for use within NHSScotland. Argenx is exploring next steps in Scotland. More information on the SMC position is available here.


Support and information

Myasthenia gravis

Myasthenia gravis (sometimes abbreviated to MG) is a chronic, autoimmune condition that causes muscle weakness and excessive muscle fatigue. It is rare, affecting about 15 in every 100,000 people in the UK.


We fund groundbreaking research to learn more about muscle wasting conditions and lead us to new treatments. We’ve already made advances that would have been unthinkable just 10 years ago, and we are determined to go even further and faster.

Our support services

We are here for everyone, but we understand that support isn’t one-size-fits-all. Speak to us. We can tailor our support to meet your unique needs.

Our helpline is open Monday-Thursday 10am-2pm.